米拉妥昔单抗soravtansine 联合治疗卵巢癌显示出令人鼓舞的应答率。
Mirvetuximab Soravtansine Combination Yields Encouraging Response Rates in Ovarian Cancer.
出版信息
Oncology (Williston Park). 2020 Jul 15;34(7):250.
PMID:32674207
Abstract
Mirvetuximab soravtansine in combination with bevacizumab (Avastin) to treat patients with platinum-agnostic ovarian cancer demonstrated a confirmed 64% overall response rate (ORR), regardless of platinum status, according to study results presented at the 2020 American Society of Clinical Oncology Virtual Scientific Program.
摘要
研究结果显示，在 2020 年美国临床肿瘤学会虚拟科学计划会议上公布的研究结果中，Mirvetuximab soravtansine 联合贝伐珠单抗（Avastin）治疗铂类药物难治性卵巢癌患者，无论铂类药物状态如何，确认的总缓解率（ORR）为 64%。
Zotero 插件